Earnings Alerts

Tenet Healthcare (THC) Earnings: Boosted FY Adjusted EBITDA Forecast and Beating Estimates

  • Tenet Increases FY Adjusted EBITDA Forecast
    • Updated forecast: $3.83 billion to $3.98 billion
    • Previous forecast: $3.50 billion to $3.70 billion
    • Analyst estimate was $3.65 billion
  • Higher Net Operating Revenue Expectations
    • Updated forecast: $20.60 billion to $21.00 billion
    • Previous forecast: $20.00 billion to $20.40 billion
    • Analyst estimate was $20.43 billion
  • Improved Third Quarter Forecast
    • Adjusted EBITDA: $900 million to $950 million
    • Analyst estimate: $828.8 million
    • Net Operating Revenue: $5.00 billion to $5.10 billion
    • Analyst estimate: $4.9 billion
  • Second Quarter Results Exceeded Expectations
    • Adjusted EBITDA: $945 million (estimate: $874.3 million)
    • Net Operating Revenue: $5.10 billion (estimate: $4.99 billion)
    • Ambulatory Care Revenue: $1.14 billion (estimate: $1.04 billion)
    • Hospital Operations and Services Revenue: $3.96 billion
  • FY 2024 Financial Outlook
    • Adjusted EBITDA: now $3.825 billion to $3.975 billion (an increase of $300 million)
    • Free Cash Flow: now $1.100 billion to $1.350 billion (an increase of $150 million)
  • CEO’s Comments on Performance
    • Growth driven by volume and revenue
    • Sustained strong operating performance
    • Second quarter results exceeded expectations
  • Analyst Ratings
    • 18 buys
    • 2 holds
    • 1 sell

Tenet Healthcare on Smartkarma

Analysts on Smartkarma are closely following Tenet Healthcare Corporation, with Baptista Research providing in-depth insights on the company’s recent performance and future prospects. In their report titled “Tenet Healthcare Corporation: What Is Their Biggest Competitive Advantage? – Major Drivers,” Baptista Research highlights Tenet’s successful sale of nine hospitals, generating $4 billion in pre-tax proceeds. This transaction has significantly reduced the company’s debt burden, enhancing capital efficiency and profitability. The focus on investing in ambulatory care programs is seen as a strategic move to drive further growth.

Furthermore, in another analysis titled “Tenet Healthcare Corporation: Initiation Of Coverage – Its Focus on Higher Acuity Services in Hospitals & Other Core Strategies! – Major Drivers,” Baptista Research applauds Tenet Healthcare‘s strong performance in Q4 2023, with impressive net operating revenues of $20.5 billion and a robust adjusted EBITDA margin of 17.2%. The company’s emphasis on quality services and innovation has contributed to its profitability. However, some challenges were noted during the earnings call, indicating areas for further improvement and strategic planning.


A look at Tenet Healthcare Smart Scores

FactorScoreMagnitude
Value3
Dividend1
Growth5
Resilience2
Momentum5
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

In analyzing Tenet Healthcare‘s long-term outlook based on the Smartkarma Smart Scores, the company appears to have a solid foundation for growth and momentum. The high scores in Growth and Momentum suggest that Tenet Healthcare is positioned well for future expansion and market performance. With a moderate score in Value, the company’s stock may be seen as reasonably priced relative to its potential for growth. However, the lower scores in Dividend and Resilience indicate areas where the company may need to focus on improving in order to enhance shareholder returns and weather potential market challenges.

Tenet Healthcare Corporation, a company that owns and operates various healthcare facilities in the United States, shows strengths in growth potential and market momentum according to the Smartkarma Smart Scores. With a diverse portfolio including specialty hospitals and medical office buildings, Tenet Healthcare aims to provide healthcare services to communities across the nation. By leveraging its strong growth and momentum factors, the company could continue to expand its market presence and enhance its overall performance in the healthcare industry.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars